Pharmacokinetics and safety of a new aspirin formulation for the acute treatment of primary headaches

Bibliography

• Vane JR, Botting M. Aspirin and other salicylates. Chapman & Hall Medical; 1992
   Google Scholar
• Yeomans ND. Aspirin: old drug, new uses and challenges. J Gastroenterol Hepatol 2011;26(3):426-31
   PubMed Web of Science ®Google Scholar
• Vane JR, Botting RM. The mechanism of action of aspirin. Thromb Res 2003;110(5-6):255-8
   PubMed Web of Science ®Google Scholar
• Bartfai T, Conti B. Fever. ScientificWorldJournal 2010;10:490-503
   Google Scholar
• Weiss HJ, Aledort LM. Impaired platelet-connective-tissue reaction in man after aspirin ingestion. Lancet 1967;2(7514):495-7
   PubMed Web of Science ®Google Scholar
• Patrono C, Bachmann F, Baigent C, et al. Expert consensus document on the use of antiplatelet agents. The task force on the use of antiplatelet agents in patients with atherosclerotic cardiovascular disease of the European society of cardiology. Eur Heart J 2004;25(2):166-81
   PubMed Web of Science ®Google Scholar
• Smith SC, Benjamin EJ, Bonow RO, et al. AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients with Coronary and other Atherosclerotic Vascular Disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation. Circulation 2011;124(22):2458-73
   PubMed Web of Science ®Google Scholar
• Burn J, Gerdes AM, Macrae F, et al. Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial. Lancet 2011;378(9809):2081-7
   PubMed Web of Science ®Google Scholar
• Flossmann E, Rothwell PM; British Doctors Aspirin Trial and the UK-TIA Aspirin Trial. Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies. Lancet 2007;369(9573):1603-13
   PubMed Web of Science ®Google Scholar
• Rothwell PM, Price JF, Fowkes FG, et al. Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials. Lancet 2012;379(9826):1602-12
   PubMed Web of Science ®Google Scholar
• Rothwell PM, Fowkes FG, Belch JF, et al. Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet 2011;377(9759):31-41
   PubMed Web of Science ®Google Scholar
• Algra AM, Rothwell PM. Effects of regular aspirin on long-term cancer incidence and metastasis: a systematic comparison of evidence from observational studies versus randomised trials. Lancet Oncol 2012;13(5):518-27
   PubMed Web of Science ®Google Scholar
• Rothwell PM, Wilson MPrice JF, et al. Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials. Lancet 2012;379(9826):1591-601
   PubMed Web of Science ®Google Scholar
• Schramm AM, Clowse ME. Aspirin for Prevention of Preeclampsia in Lupus Pregnancy. Autoimmune Dis 2014;2014:920467
   PubMedGoogle Scholar
• Meiri H, Sammar M, Herzog A, et al. Prediction of preeclampsia by placental protein 13 and background risk factors and its prevention by aspirin. J Perinat Med 2014. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Meyer JS, Rogers RL, McClintic K, et al. Randomized clinical trial of daily aspirin therapy in multi-infarct dementia. A pilot study. J Am Geriatr Soc 1989;37(6):549-55
   PubMed Web of Science ®Google Scholar
• Pomponi MF, Gambassi G, Pomponi M, et al. Why docosahexaenoic acid and aspirin supplementation could be useful in women as a primary prevention therapy against Alzheimer’s disease? Ageing Res Rev 2011;10(1):124-31
   PubMed Web of Science ®Google Scholar
• Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol 1971;231(25):232-5
   PubMedGoogle Scholar
• Smith JB, Willis AL. Aspirin selectively inhibits prostaglandin production in human platelets. Nat New Biol 1971;231(25):235-7
   PubMedGoogle Scholar
• Simmons DL, Botting RM, Hla T. Cyclooxygenase isozymes: the biology of prostaglandin synthesis and inhibition. Pharmacol Rev 2004;56(3):387-437
   PubMed Web of Science ®Google Scholar
• Ricciotti E, FitzGerald GA. Prostaglandins and inflammation. Arterioscler Thromb Vasc Biol 2011;31(5):986-1000
   PubMed Web of Science ®Google Scholar
• Salvemini D, Kim SF, Mollace V. Reciprocal regulation of the nitric oxide and cyclooxygenase pathway in pathophysiology: relevance and clinical implications. Am J Physiol Regul Integr Comp Physiol 2013;304(7):R473-87
   PubMed Web of Science ®Google Scholar
• Narumiya S. Prostanoids and inflammation: a new concept arising from receptor knockout mice. J Mol Med (Berl) 2009;87(10):1015-22
   PubMed Web of Science ®Google Scholar
• Cesare P, McNaughton P. Peripheral pain mechanisms. Curr Opin Neurobiol 1997;7(4):493-9
   PubMed Web of Science ®Google Scholar
• Tosco P. A mechanistic hypothesis for the aspirin-induced switch in lipid mediator production by cyclooxygenase-2. J Am Chem Soc 2013;135(28):10404-10
   PubMed Web of Science ®Google Scholar
• Warner TD, Mitchell JA. Cyclooxygenases: new forms, new inhibitors, and lessons from the clinic. FASEB J 2004;18(7):790-804
   PubMed Web of Science ®Google Scholar
• Mitchell JA, Akarasereenont P, Thiemermann C, et al. Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase. Proc Natl Acad Sci USA 1993;90(24):11693-7
   PubMed Web of Science ®Google Scholar
• Thun MJ, Jacobs EJ, Patrono C. The role of aspirin in cancer prevention. Nat Rev Clin Oncol 2012;9(5):259-67
   PubMed Web of Science ®Google Scholar
• Serhan CN, Yacoubian S, Yang R. Anti-inflammatory and proresolving lipid mediators. Annu Rev Pathol 2008;3:279-312
   PubMed Web of Science ®Google Scholar
• Dalli J, Winkler JW, Colas RA, et al. Resolvin D3 and aspirin-triggered resolvin D3 are potent immunoresolvents. Chem Biol 2013;20(2):188-201
   PubMed Web of Science ®Google Scholar
• Muir N, Nichols JD, Stillings MR, et al. Comparative bioavailability of aspirin and paracetamol following single dose administration of soluble and plain tablets. Curr Med Res Opin 1997;13(9):491-500
   PubMed Web of Science ®Google Scholar
• Muir N, Nichols JD, Clifford JM, et al. The influence of dosage form on aspirin kinetics: implications for acute cardiovascular use. Curr Med Res Opin 1997;13(10):547-53
   PubMed Web of Science ®Google Scholar
• Stillings M, Havlik I, Chetty M, et al. Comparison of the pharmacokinetic profiles of soluble aspirin and solid paracetamol tablets in fed and fasted volunteers. Curr Med Res Opin 2000;16(2):115-24
   PubMed Web of Science ®Google Scholar
• Sagar KA, Smyth MR. A comparative bioavailability study of different aspirin formulations using on-line multidimensional chromatography. J Pharm Biomed Anal 1999;21(2):383-92
   PubMed Web of Science ®Google Scholar
• Brandon RA, Eadie MJ, Curran AC, et al. A new formulation of aspirin: bioavailability and analgesic efficacy in migraine attacks. Cephalalgia 1986;6(1):19-27
   PubMed Web of Science ®Google Scholar
• Farinelli I, Martelletti P. Aspirin and tension-type headache. J Headache Pain 2007;8(1):49-55
   PubMedGoogle Scholar
• Voelker M, Hammer M. Dissolution and pharmacokinetics of a novel micronized aspirin formulation. Inflammopharmacology 2012;20(4):225-31
   PubMedGoogle Scholar
• Mustapha A, Yakasai IA, Aguye IA. Effect of Tamarindus indica L. on the bioavailability of aspirin in healthy human volunteers. Eur J Drug Metab Pharmacokinet 1996;21(3):223-6
   PubMed Web of Science ®Google Scholar
• Hsyu PH, Cox JW, Pullen RH, et al. Pharmacokinetic interactions between arbaprostil and aspirin in humans. Biopharm Drug Dispos 1989;10(4):411-22
   PubMed Web of Science ®Google Scholar
• Kershaw RA, Mays DC, Bianchine JR, et al. Disposition of aspirin and its metabolites in the semen of man. J Clin Pharmacol 1987;27(4):304-9
   PubMed Web of Science ®Google Scholar
• Corrocher R, Bambara LM, Caramaschi P, et al. Effect of ranitidine on the absorption of aspirin. Digestion 1987;37(3):178-83
   PubMed Web of Science ®Google Scholar
• Latini R, Cerletti C, de Gaetano G, et al. Comparative bioavailability of aspirin from buffered, enteric-coated and plain preparations. Int J Clin Pharmacol Ther Toxicol 1986;24(6):313-18
   PubMedGoogle Scholar
• Helliwell M, Gibson T, Berry D, et al. A pharmacokinetic comparison of choline magnesium trisalicylate and soluble aspirin. Br J Rheumatol 1984;23(4):288-91
   PubMedGoogle Scholar
• Yoovathaworn KC, Sriwatanakul K, Thithapandha A. Influence of caffeine on aspirin pharmacokinetics. Eur J Drug Metab Pharmacokinet 1986;11(1):71-6
   PubMed Web of Science ®Google Scholar
• Krivosíková Z, Spustová V, Dzúrik R. A highly sensitive HPLC method for the simultaneous determination of acetylsalicylic, salicylic and salicyluric acids in biologic fluids: pharmacokinetic, metabolic and monitoring implications. Methods Find Exp Clin Pharmacol 1996;18(8):527-32
   PubMed Web of Science ®Google Scholar
• Yiannakopoulou E. Pharmacogenomics of acetylsalicylic acid and other nonsteroidal anti-inflammatory agents: clinical implications. Eur J Clin Pharmacol 2013;69(7):1369-73
   PubMed Web of Science ®Google Scholar
• Gatti G, Barzaghi N, Attardo Parrinello G, et al. Pharmacokinetics of salicylic acid following administration of aspirin tablets and three different forms of soluble aspirin in normal subjects. Int J Clin Pharmacol Res 1989;9(6):385-9
   PubMedGoogle Scholar
• Bhala N, Emberson J, Merhi A, et al. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet 2013;382(9894):769-79
   PubMed Web of Science ®Google Scholar
• Douglas RA, Johnston ED. Aspirin and chronic gastric ulcer. Med J Aust 1961;48(2):893-7
   PubMed Web of Science ®Google Scholar
• Gillies MA, Skyring A. Gastric and duodenal ulcer. The association between aspirin ingestion, smoking and family history of ulcer. Med J Aust 1969;2(6):280-5
   PubMed Web of Science ®Google Scholar
• Yeomans ND, Lanas AI, Talley NJ, et al. Prevalence and incidence of gastroduodenal ulcers during treatment with vascular protective doses of aspirin. Aliment Pharmacol Ther 2005;22(9):795-801
   PubMed Web of Science ®Google Scholar
• McCarthy DM. Efficacy and gastrointestinal risk of aspirin used for the treatment of pain and cold. Best Pract Res Clin Gastroenterol 2012;26(2):101-12
   PubMed Web of Science ®Google Scholar
• De Berardis G, Lucisano G, D’Ettorre A, et al. Association of aspirin use with major bleeding in patients with and without diabetes. JAMA 2012;307(21):2286-94
   PubMed Web of Science ®Google Scholar
• Lanas A, Wu P, Medin J, et al. Low doses of acetylsalicylic acid increase risk of gastrointestinal bleeding in a meta-analysis. Clin Gastroenterol Hepatol 2011;9(9):762-768.e6
   PubMed Web of Science ®Google Scholar
• Baron JA, Senn S, Voelker M, et al. Gastrointestinal adverse effects of short-term aspirin use: a meta-analysis of published randomized controlled trials. Drugs R D 2013;13(1):9-16
   PubMedGoogle Scholar
• Rampal P, Moore N, Van Ganse E, et al. Gastrointestinal tolerability of ibuprofen compared with paracetamol and aspirin at over-the-counter doses. J Int Med Res 2002;30(3):301-8
   PubMed Web of Science ®Google Scholar
• Lanas A, McCarthy D, Voelker M, et al. Short-term acetylsalicylic acid (aspirin) use for pain, fever, or colds - gastrointestinaladverse effects: a meta-analysis of randomized clinical trials. Drugs R D 2011;11(3):277-88
   PubMedGoogle Scholar
• Steiner TJ, Voelker M. Gastrointestinal tolerability of aspirin and the choice of over-the-counter analgesia for short-lasting acute pain. J Clin Pharm Ther 2009;34(2):177-86
   PubMed Web of Science ®Google Scholar
• Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 2000;343(21):1520-8
   PubMed Web of Science ®Google Scholar
• Bhosale UA, Quraishi N, Yegnanarayan R, et al. A comparative study to evaluate the cardiovascular risk of selective and nonselective cyclooxygenase inhibitors (COX-Is) in arthritic patients. J Basic Clin Physiol Pharmacol 2014. [Epub ahead of print]
   Google Scholar
• McGettigan P, Henry D. Cardiovascular risk with non-steroidal anti-inflammatory drugs: systematic review of population-based controlled observational studies. PLoS Med 2011;8(9):e1001098
   PubMed Web of Science ®Google Scholar
• McGettigan P, Henry D. Use of non-steroidal anti-inflammatory drugs that elevate cardiovascular risk: an examination of sales and essential medicines lists in low-, middle-, and high-income countries. PLoS Med 2013;10(2):e1001388
   PubMed Web of Science ®Google Scholar
• Curhan GC, Willett WC, Rosner B, et al. Frequency of analgesic use and risk of hypertension in younger women. Arch Intern Med 2002;162(19):2204-8
   PubMed Web of Science ®Google Scholar
• Forman JP, Rimm EB, Curhan GC. Frequency of analgesic use and risk of hypertension among men. Arch Intern Med 2007;167(4):394-9
   PubMed Web of Science ®Google Scholar
• Perneger TV, Whelton PK, Klag MJ. Risk of kidney failure associated with the use of acetaminophen, aspirin, and nonsteroidal antiinflammatory drugs. N Engl J Med 1994;331(25):1675-9
   PubMed Web of Science ®Google Scholar
• Sandler DP, Smith JC, Weinberg CR, et al. Analgesic use and chronic renal disease. N Engl J Med 1989;320(19):1238-43
   PubMed Web of Science ®Google Scholar
• Tolman KG. Hepatotoxicity of non-narcotic analgesics. Am J Med 1998;105(1B):13S-9S
   PubMedGoogle Scholar
• Agúndez JA, Lucena MI, Martìnez C, et al. Assessment of nonsteroidal anti-inflammatory drug-induced hepatotoxicity. Expert Opin Drug Metab Toxicol 2011;7(7):817-28
   PubMed Web of Science ®Google Scholar
• Carvajal A, Prieto JR, Alvarez Requejo A, et al. Aspirin or acetaminophen? A comparison from data collected by the Spanish Drug Monitoring System. J Clin Epidemiol 1996;49(2):255-61
   PubMed Web of Science ®Google Scholar
• Guggenheimer J, Moore PA. The therapeutic applications of and risks associated with acetaminophen use: a review and update. J Am Dent Assoc 2011;142(1):38-44
   PubMed Web of Science ®Google Scholar
• Bessone F. Non-steroidal anti-inflammatory drugs: what is the actual risk of liver damage? World J Gastroenterol 2010;16(45):5651-61
   PubMed Web of Science ®Google Scholar
• Amar PJ, Schiff ER. Acetaminophen safety and hepatotoxicity--where do we go from here? Expert Opin Drug Saf 2007;6(4):341-55
   PubMed Web of Science ®Google Scholar
• McGill MR, Jaeschke H. Metabolism and disposition of acetaminophen: recent advances in relation to hepatotoxicity and diagnosis. Pharm Res 2013;30(9):2174-87
   PubMed Web of Science ®Google Scholar
• Glasgow JF, Middleton B. Reye syndrome--insights on causation and prognosis. Arch Dis Child 2001;85(5):351-3
   PubMed Web of Science ®Google Scholar
• Kamienski MC. Reye syndrome. Am J Nurs 2003;103(7):54-7
   PubMed Web of Science ®Google Scholar
• Belay ED, Bresee JS, Holman RC, et al. Reye’s syndrome in the United States from 1981 through 1997. N Engl J Med 1999;340(18):1377-82
   PubMed Web of Science ®Google Scholar
• Forsyth BW, Horwitz RI, Acampora D, et al. New epidemiologic evidence confirming that bias does not explain the aspirin/Reye’s syndrome association. JAMA 1989;261(17):2517-24
   PubMed Web of Science ®Google Scholar
• Gollapudi RR, Teirstein PS, Stevenson DD, et al. Aspirin sensitivity: implications for patients with coronary artery disease. JAMA 2004;292(24):3017-23
   PubMed Web of Science ®Google Scholar
• Garcia Cruz ML, Jimenez-Chobillon MA, Teran LM. Rhinosinusitis and aspirin-exacerbated respiratory disease. J Allergy (Cairo) 2012;2012:273752
   PubMedGoogle Scholar
• Stevenson DD. Aspirin and NSAID sensitivity. Immunol Allergy Clin North Am 2004;24(3):491-505
   PubMed Web of Science ®Google Scholar
• Szczeklik A. Prostaglandin E2 and aspirin-induced asthma. Lancet 1995;345(8956):1056
   PubMed Web of Science ®Google Scholar
• Kim SH, Sanak M, Park HS. Genetics of hypersensitivity to aspirin and nonsteroidal anti-inflammatory drugs. Immunol Allergy Clin North Am 2013;33(2):177-94
   PubMed Web of Science ®Google Scholar
• Sánchez-Borges M, Caballero-Fonseca F, Capriles-Hulett A. Aspirin-exacerbated cutaneous disease. Immunol Allergy Clin North Am 2013;33(2):251-62
   PubMed Web of Science ®Google Scholar
• Moore-Robinson M, Warin RP. Effect of salicylates in urticaria. Br Med J 1967;4(5574):262-4
   PubMed Web of Science ®Google Scholar
• Nosbaum A, Braire-Bourrel M, Dubost R, et al. Prevention of nonsteroidal inflammatory drug-induced urticaria and/or angioedema. Ann Allergy Asthma Immunol 2013;110(4):263-6
   PubMed Web of Science ®Google Scholar
• Diener HC, Lampl C, Reimnitz P, et al. Aspirin in the treatment of acute migraine attacks. Expert Rev Neurother 2006;6(4):563-73
   PubMedGoogle Scholar
• Lampl C, Voelker M, Diener HC. Efficacy and safety of 1,000 mg effervescent aspirin: individual patient data meta-analysis of three trials in migraine headache and migraine accompanying symptoms. J Neurol 2007;254(6):705-12
   PubMed Web of Science ®Google Scholar
• Kirthi V, Derry S, Moore RA, et al. Aspirin for acute migraine headaches in adults. J Neurol Neurosurg Psychiatry 2013;84(5):585-6
   PubMed Web of Science ®Google Scholar
• Lange R, Schwarz JA, Hohn M. Acetylsalicylic acid effervescent 1000 mg (Aspirin) in acute migraine attacks; a multicentre, randomized, double-blind, single-dose, placebo-controlled parallel group study. Cephalalgia 2000;20(7):663-7
   PubMed Web of Science ®Google Scholar
• MacGregor EA, Dowson A, Davies PT. Mouth-dispersible aspirin in the treatment of migraine: a placebo-controlled study. Headache 2002;42(4):249-55
   PubMed Web of Science ®Google Scholar
• Lipton RB, Goldstein J, Baggish JS, et al. Aspirin is efficacious for the treatment of acute migraine. Headache 2005;45(4):283-92
   PubMed Web of Science ®Google Scholar
• Henry P, Hiesse-Provost O, Dillenschneider A, et al. [Efficacy and tolerance of an effervescent aspirin-metoclopramide combination in the treatment of a migraine attack. Randomized double-blind study using a placebo]. Presse Med 1995;24(5):254-8
   PubMed Web of Science ®Google Scholar
• Chabriat H, Joire JE, Danchot J, et al. Combined oral lysine acetylsalicylate and metoclopramide in the acute treatment of migraine: a multicentre double-blind placebo-controlled study. Cephalalgia 1994;14(4):297-300
   PubMed Web of Science ®Google Scholar
• Geraud G, Compagnon A, Rossi A, et al. Zolmitriptan versus a combination of acetylsalicylic acid and metoclopramide in the acute oral treatment of migraine: a double-blind, randomised, three-attack study. Eur Neurol 2002;47(2):88-98
   PubMed Web of Science ®Google Scholar
• Tfelt-Hansen P. The effectiveness of combined oral lysine acetylsalicylate and metoclopramide (Migpriv) in the treatment of migraine attacks. Comparison with placebo and oral sumatriptan. Funct Neurol 2000;15(Suppl 3):196-201
   PubMed Web of Science ®Google Scholar
• Tfelt-Hansen P, Olesen J. Effervescent metoclopramide and aspirin (Migravess) versus effervescent aspirin or placebo for migraine attacks: a double-blind study. Cephalalgia 1984;4(2):107-11
   PubMed Web of Science ®Google Scholar
• Diener HC, Eikermann A, Gessner U, et al. Efficacy of 1,000 mg effervescent acetylsalicylic acid and sumatriptan in treating associated migraine symptoms. Eur Neurol 2004;52(1):50-6
   PubMed Web of Science ®Google Scholar
• Diener HC, Bussone G, de Liano H, et al. Placebo-controlled comparison of effervescent acetylsalicylic acid, sumatriptan and ibuprofen in the treatment of migraine attacks. Cephalalgia 2004;24(11):947-54
   PubMed Web of Science ®Google Scholar
• Lampl C, Voelker M, Steiner TJ. Aspirin is first-line treatment for migraine and episodic tension-type headache regardless of headache intensity. Headache 2012;52(1):48-56
   PubMed Web of Science ®Google Scholar
• Boureau F, Joubert JF, Lasserre V, et al. Double-blind comparison of an acetaminophen 400 mg-codeine 25 mg combination versus aspirin 1000 mg and placebo in acute migraine attack. Cephalalgia 1994;14(2):156-61
   PubMed Web of Science ®Google Scholar
• Titus F, Escamilla C, Gomes de Costa Palmeira MM, et al. A double-blind comparison of lysine acetylsalicylate plus metoclopramide vs ergotamine plus caffeine in migraine. J Clin Drug Invest 2001;21(2):8
   Google Scholar
• Le Jeunne C, Gómez JP, Pradalier A, et al. Comparative efficacy and safety of calcium carbasalate plus metoclopramide versus ergotamine tartrate plus caffeine in the treatment of acute migraine attacks. Eur Neurol 1999;41(1):37-43
   PubMed Web of Science ®Google Scholar
• Limmroth V, May A, Diener H. Lysine-acetylsalicylic acid in acute migraine attacks. Eur Neurol 1999;41(2):88-93
   PubMed Web of Science ®Google Scholar
• Tfelt-Hansen P, Henry P, Mulder LJ, et al. The effectiveness of combined oral lysine acetylsalicylate and metoclopramide compared with oral sumatriptan for migraine. Lancet 1995;346(8980):923-6
   PubMed Web of Science ®Google Scholar
• A study to compare oral sumatriptan with oral aspirin plus oral metoclopramide in the acute treatment of migraine. The Oral Sumatriptan and Aspirin plus Metoclopramide Comparative Study Group. Eur Neurol 1992;32(3):177-84
   PubMed Web of Science ®Google Scholar
• Nebe J, Heier M, Diener HC. Low-dose ibuprofen in self-medication of mild to moderate headache: a comparison with acetylsalicylic acid and placebo. Cephalalgia 1995;15(6):531-5
   PubMed Web of Science ®Google Scholar
• Kirthi V, Derry S, Moore RA. Aspirin with or without an antiemetic for acute migraine headaches in adults. Cochrane Database Syst Rev 2013;4:CD008041
   PubMedGoogle Scholar
• Derry CJ, Derry S, Moore RA. Sumatriptan (oral route of administration) for acute migraine attacks in adults. Cochrane Database Syst Rev 2012;2:CD008615
   PubMed Web of Science ®Google Scholar
• Derry S, Rabbie R, Moore RA. Diclofenac with or without an antiemetic for acute migraine headaches in adults. Cochrane Database Syst Rev 2013;4:CD008783
   PubMedGoogle Scholar
• Derry S, Moore RA. Paracetamol (acetaminophen) with or without an antiemetic for acute migraine headaches in adults. Cochrane Database Syst Rev 2013;4:CD008040
   PubMedGoogle Scholar
• Rabbie R, Derry S, Moore RA. Ibuprofen with or without an antiemetic for acute migraine headaches in adults. Cochrane Database Syst Rev 2013;4:CD008039
   PubMedGoogle Scholar
• Langemark M, Olesen J. Effervescent ASA versus solid ASA in the treatment of tension headache. A double-blind, placebo controlled study. Headache 1987;27(2):90-5
   PubMed Web of Science ®Google Scholar
• Steiner TJ, Lange R, Voelker M. Aspirin in episodic tension-type headache: placebo-controlled dose-ranging comparison with paracetamol. Cephalalgia 2003;23(1):59-66
   PubMed Web of Science ®Google Scholar
• Peters BH, Fraim CJ, Masel BE. Comparison of 650 mg aspirin and 1,000 mg acetaminophen with each other, and with placebo in moderately severe headache. Am J Med 1983;74(6A):36-42
   PubMed Web of Science ®Google Scholar
• Gatoulis SC, Voelker M, Fisher M. Assessment of the efficacy and safety profiles of aspirin and acetaminophen with codeine: results from 2 randomized, controlled trials in individuals with tension-type headache and postoperative dental pain. Clin Ther 2012;34(1):138-48
   PubMed Web of Science ®Google Scholar
• Martínez-Martín P, Raffaelli E, Titus F, et al. Efficacy and safety of metamizol vs. acetylsalicylic acid in patients with moderate episodic tension-type headache: a randomized, double-blind, placebo- and active-controlled, multicentre study. Cephalalgia 2001;21(5):604-10
   PubMed Web of Science ®Google Scholar
• Tfelt-Hansen P. Triptans vs other drugs for acute migraine. Are there differences in efficacy? A comment. Headache 2008;48(4):601-5
   PubMed Web of Science ®Google Scholar
• MacGregor EA, Steiner TJ, Davies PTG. Guidelines for all healthcare professionals in the diagnosis and management of migraine, tension-type headache, cluster headache, medication-overuse headache. 2010; British Association for the Study of Headache. Available from: http://www.migraineclinic.org.uk/medical-proffesionals/bash-guidelines/ [Last accessed Jun 2014]
   Google Scholar
• Matchar DB, Young WB, Rosenberg JH, et al. Evidence-Based Guidelines for Migraine Headache in the Primary Care Setting: Pharmacological Management of Acute Attacks. 2012; American Academy of Neurology. Available from: http://tools.aan.com/professionals/practice/pdfs/gl0087.pdf [Last accessed Jun 2014]
   Google Scholar
• Silberstein SD. Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2000;55(6):754-62
   PubMed Web of Science ®Google Scholar
• Sarchielli P, Granella F, Prudenzano MP, et al. Italian guidelines for primary headaches: 2012 revised version. J Headache Pain 2012;13(Suppl 2):S31-70
   PubMed Web of Science ®Google Scholar
• Lanteri-Minet M, Valade D, Geraud G, et al. Revised French guidelines for the diagnosis and management of migraine in adults and children. J Headache Pain 2014;15(1):2
   PubMed Web of Science ®Google Scholar
• Bendtsen L, Birk S, Kasch H, et al. Reference programme: diagnosis and treatment of headache disorders and facial pain. Danish Headache Society, 2nd Edition, 2012. J Headache Pain 2012;13(Suppl 1):S1-29
   PubMedGoogle Scholar
• Davies GM, Santanello N, Lipton R. Determinants of patient satisfaction with migraine therapy. Cephalalgia 2000;20(6):554-60
   PubMed Web of Science ®Google Scholar
• Fox AW. Onset of effect of 5-HT1B/1D agonists: a model with pharmacokinetic validation. Headache 2004;44(2):142-7
   PubMed Web of Science ®Google Scholar
• Cooper SA, Voelker M. Evaluation of onset of pain relief from micronized aspirin in a dental pain model. Inflammopharmacology 2012;20(4):233-42
   PubMedGoogle Scholar